Equities analysts expect that Aileron Therapeutics Inc (NASDAQ:ALRN) will report ($0.10) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.10). Aileron Therapeutics posted earnings of ($0.28) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 64.3%. The firm is expected to announce its next quarterly earnings report on Thursday, November 5th.
On average, analysts expect that Aileron Therapeutics will report full year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.54). For the next fiscal year, analysts expect that the business will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.74) to ($0.36). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05.
A number of research firms recently weighed in on ALRN. HC Wainwright reissued a “buy” rating on shares of Aileron Therapeutics in a research note on Tuesday, August 4th. Zacks Investment Research lowered shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. William Blair reissued a “buy” rating on shares of Aileron Therapeutics in a research note on Monday, August 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Aileron Therapeutics in a research note on Tuesday, June 2nd.
NASDAQ:ALRN traded up $0.01 on Tuesday, hitting $1.16. 444,147 shares of the stock were exchanged, compared to its average volume of 536,598. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.99 and a current ratio of 3.99. Aileron Therapeutics has a 52 week low of $0.25 and a 52 week high of $1.99. The stock has a market capitalization of $45.54 million, a price-to-earnings ratio of -1.26 and a beta of 3.65. The company’s 50-day moving average price is $1.17 and its 200 day moving average price is $0.85.
In other news, Director Rickenbach Josef H. Von bought 227,272 shares of the stock in a transaction on Monday, June 8th. The stock was purchased at an average price of $1.10 per share, with a total value of $249,999.20. Following the completion of the purchase, the director now owns 445,460 shares of the company’s stock, valued at $490,006. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.20% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $28,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aileron Therapeutics during the second quarter worth $29,000. Geode Capital Management LLC lifted its position in Aileron Therapeutics by 67.1% in the 4th quarter. Geode Capital Management LLC now owns 91,895 shares of the company’s stock valued at $52,000 after acquiring an additional 36,893 shares in the last quarter. Finally, Personal CFO Solutions LLC boosted its stake in Aileron Therapeutics by 106.0% in the 2nd quarter. Personal CFO Solutions LLC now owns 47,388 shares of the company’s stock worth $56,000 after purchasing an additional 24,388 shares during the period. 9.94% of the stock is currently owned by institutional investors.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Article: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.